Two Sigma Securities’s NeuroSense Therapeutics NRSN Stock Holding History

Two Sigma Securities’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-14,705	Closed	-$13.7K	–	1897
2025 Q1	$13.7K	Sell	14,705 -312	-2%	-$345	﹤0.01%	1171
2024 Q4	$18K	Buy	+15,017	New	+$17.3K	﹤0.01%	1336

Other funds holding NRSN

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Securities's NRSN Position: Q2 2025 in Review

Two Sigma Securities sold out of NeuroSense Therapeutics (NRSN) in Q2 2025, closing a stake of 14,705 shares — an estimated $13.7K sold.

Two Sigma Securities first reported a position in NRSN in Q4 2024 and held it in 2 quarters. The position peaked at $18K in Q4 2024. 17 funds tracked by Wall St. Rank hold NRSN as of Q2 2025.

Two Sigma Securities reported no remaining NeuroSense Therapeutics position as of Q2 2025 after selling out during the quarter.
Two Sigma Securities sold 14,705 NeuroSense Therapeutics shares in Q2 2025, an estimated $13.7K.
Two Sigma Securities first reported a position in NeuroSense Therapeutics in Q4 2024 and held it in 2 quarters.
Two Sigma Securities's NeuroSense Therapeutics position peaked at $18K in Q4 2024.
17 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2025.

Based on Two Sigma Securities's 13F filing for Q2 2025, filed 14 Aug 2025.